While therapeutic targets such as Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Progesteron Receptor (PR) have improved treatment strategies for certain BC subtypes, further research is needed to identify additional molecular players involved in cancer progression. Here, ERBB2 is linked to breast cancer.